[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-cancer-papillary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-cancer-papillary":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,99,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100572211","surgical-competency-for-robot-assisted-thyroidectomy-construction-and-validation-of-a-robotic-thyroidectomy-assessment-score-rtas-100572211",false,"NCT06730321","Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodules with a maximum diameter not exceeding 6 cm\n* Participants with high cosmetic expectations\n* Participants underwent robotic thyroidectomy without open conversion\n\nExclusion Criteria:\n\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of distant invasion\n* Participants with fusion or fixed of lymph nodes in the neck","ALL",{"count":17,"type":18},200,"ESTIMATED","6 Months","OBSERVATIONAL","To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).",[23,24,25,26,27],"Thyroid Cancer","Thyroid Nodule","Thyroid Diseases","Thyroid Cancer, Papillary","Thyroid Cancer, Follicular",[29,30,31],"Robotic thyroidectomy","Surgical competency","Robotic thyroidectomy assessment score","RECRUITING","2026-05-02",{"date":35,"type":36},"2026-05-07","ACTUAL",{"date":38,"type":36},"2024-12-12",{"date":40,"type":18},"2027-12-31",{"name":42,"class":43},"Shanghai 6th People's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":73,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100498278","phase-2-determine-trial-treatment-arm-05-vemurafenib-in-combination-with-cobimetinib-in-adult-patients-with-braf-positive-cancers-100498278","NCT05768178","DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 05 (VEMURAFENIB AND COBIMETINIB) OUTLINED BELOW\\*\n\n\\*When vemurafenib and cobimetinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the vemurafenib and cobimetinib-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated next-generation sequencing method.\n\nB. Adult patients ≥18 years old.\n\nC. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nD. Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nE. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n* Have a negative serum or urine pregnancy test before enrolment and;\n* Agree to sexual abstinence OR to use any two forms of highly effective or effective methods together (at least one to be non-hormonal) such as:\n\n  * Highly effective methods:\n* combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)\n* progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)\n* intrauterine device (IUD)\n* intrauterine hormone-releasing system (IUS)\n* bilateral tubal occlusion\n* vasectomised partner\n\n  * Effective methods:\n* progestogen-only oral hormonal contraception not associated with inhibition of ovulation\n* male or female condom with or without spermicide\n* cap, diaphragm or sponge with spermicide\n\nEffective from the first administration of vemurafenib or cobimetinib (whichever is first), throughout the trial and for six months after the last administration of vemurafenib or cobimetinib (whichever is later).\n\nF. Male patients with partners who are women of childbearing potential, are eligible provided that they agree to the following, from the first administration of vemurafenib or cobimetinib (whichever is first), throughout the trial and for six months after the last administration of vemurafenib or cobimetinib (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception as in E, above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nExclusion Criteria:\n\nA. Diagnosis of unresectable or metastatic melanoma with a BRAF V600 mutation.\n\nB. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for six months following their last dose of vemurafenib or cobimetinib, whichever is later.\n\nC. Patients with QTcF (Corrected QT interval by Fridericia) at screening of \\>450 ms for males and \\>470 ms for females measured on triplicate ECG (if 1\u002F3 readings show \\>450\u002F470 ms then patient is ineligible).\n\nD. Patients with any history of long QT syndrome or Torsades de Pointes (or any concurrent medication with a known risk of inducing Torsades de Pointes).\n\nE. Known hypersensitivity to vemurafenib or cobimetinib or any of the excipients.\n\nF. Patients unable to swallow vemurafenib and cobimetinib intact, without chewing or crushing the tablets (as per the dosing schedule).\n\nG. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during vemurafenib and cobimetinib treatment or within six months after the final dose of vemurafenib and cobimetinib.\n\nH. Patients with clinically significant pre-existing cardiac conditions including (within the last three months prior to screening):\n\n* Uncontrolled or symptomatic angina,\n* Uncontrolled atrial or ventricular arrhythmias,\n* Class III \\& IV New York Heart Association congestive heart failure,\n* Left ventricular ejection fraction (LVEF) \\\u003C50%,\n* Myocardial infarction\n\nI. Ophthalmological disorders: History of retinal detachment, severe visual impairment, central serous chorioretinopathy, neovascular retinopathy, or retinopathy of prematurity.\n\nPatients with low grade gliomas causing visual impairment may be considered eligible and monitored with close ophthalmological monitoring.\n\nJ. History of pancreatitis.\n\nK. History of central nervous system (CNS) or gastrointestinal (GI) haemorrhage within three months of trial entry.\n\nL. Patients with any history of haemorrhagic stroke.\n\nM. Prior treatment with the same class of drug unless presence of a resistance alteration known to be potentially sensitive to either vemurafenib or cobimetinib. Prior sorafenib use is permissible following a washout period of 10 days.\n\nN. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.\n\nO. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of vemurafenib and cobimetinib, including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002F acquired immune deficiency syndrome-associated opportunistic infection in the last 12 months.","18 Years",{"count":55,"type":18},30,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nCobimetinib and vemurafenib work in patients with these types of cancers which have certain changes in the cancer cells called BRAF V600 mutation-positive.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which are also BRAF V600 mutation-positive. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[62,63,26,64,65,66,67,68,69,70,71,72],"Haematological Malignancy","Melanoma","Ovarian Neoplasms","Colorectal Neoplasms","Laryngeal Neoplasms","Carcinoma, Non-Small-Cell Lung","Glioma","Multiple Myeloma","Erdheim-Chester Disease","Thyroid Carcinoma, Anaplastic","Solid Tumour",[74,75,76,77,78,79,80,81,82,83,84,85,86,87,88],"Adult","Antineoplastic Agents","Cancer","Malignancy","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Type","Neoplasms by Site","Precision Medicine","Cobimetinib","Proto-Oncogene Proteins B-raf","Rare","Tumour-agnostic","Vemurafenib","2025-11-19",{"date":91,"type":36},"2025-11-24",{"date":93,"type":36},"2023-03-01",{"date":95,"type":18},"2029-10",{"name":97,"class":43},"Cancer Research UK",16,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100535671","intraoperative-neuromuscular-monitoring-and-its-impact-on-pre--and-postoperative-acoustic-outcomes-in-thyroid-surgery-100535671","NCT06254859","Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery","Inclusion Criteria:\n\n* Age 20-60 years old.\n* Planned conventional unilateral thyroid lobectomy + isthmus resection + central compartment lymph node dissection.\n\nExclusion Criteria:\n\n* History of past head and neck surgeries.\n* Pronunciation system defect and disorder history.\n* History of vocal cord polyps or nodules.\n* History of upper respiratory tract infection in the 2 weeks before surgery or postoperative infection history.\n* History of neurological disorders.\n* Abnormalities in the throat.\n* Preoperative damage to throat morphology or motor function.\n* Preoperative functional voice or language disorders, noticeable hoarseness, or difficulty in pronunciation.\n* Pre- and postoperative laryngoscopic examination showing vocal cord paralysis and arytenoid joint dislocation.\n* Neurological disorders causing abnormal throat function.\n* Patient unable to cooperate with VHI (Voice Handicap Index) assessment and voice spectrum examination.",{"count":106,"type":18},100,"This study examines the impact of intraoperative recurrent laryngeal nerve monitoring signal changes on the postoperative voice quality of thyroid surgery patients. By analyzing extensive surgical data and postoperative voice recordings, the investigation seeks to identify patterns in the variations of these signals and their correlation with voice quality outcomes. The goal is to enhance clinical understanding and surgical practices, allowing for more precise assessments of nerve function, informed surgical interventions, and improved postoperative patient well-being.",[23,26],[110,111],"acoustic analysis","thyroid cancer","2025-05-17",{"date":114,"type":36},"2025-05-20",{"date":116,"type":36},"2024-03-01",{"date":118,"type":18},"2025-12-31",{"name":120,"class":43},"Fujian Medical University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":44},"100571847","ultrasound-guided-microwave-ablation-vs-surgery-for-low-risk-papilarythyroid-carcinoma-100571847","NCT06725576","Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma","Ultrasound and Gene-Guided Microwave Ablation Versus Surgery for Low-Risk Papillary Thyroid Carcinoma: a Prospective Observational Cohort Study.","The inclusion criteria of this study were as followed:\n\n1. PTC confirmed by fine-needle aspiration (FNA);\n2. Confirmed low-risk mutation types by next-generation sequencing (NGS) before surgery;\n3. No severe functional diseases, such as heart failure, severe respiratory diseases, or renal failure;\n4. Availability of complete follow-up data.\n\nThe exclusion criteria were as followed:\n\n1. No local or distant metastasis assessed by imaging evaluations, including ultrasound or computed tomography (CT);\n2. Lacking of preoperative genetic testing or inability to assess genetic test results;\n3. Inability to complete follow-up or lost to follow-up during the study.\n\nLow-risk PTC is defined as:\n\n1. Maximum tumor diameter ≤1 cm;\n2. Solitary lesion;\n3. No local or distant metastasis;\n4. No tumor invasion into extrathyroidal tissues;\n5. No vascular invasion;\n6. Non-invasive pathological subtype for the primary lesion (invasive subtypes include tall cell, columnar cell, diffuse sclerosing, solid\u002Ftrabecular, and oncocytic vari ants);\n7. No history of head and neck radiotherapy during adolescence;\n8. No family history of thyroid cancer;\n9. Genetic testing showing BRAF V600E mutation (without concurrent TERT mutation), RAS family gene mutations, (HRAS, NRAS, KRAS), or other low-risk mutations, such as isolated RET\u002FPTC) rearrangements.\n\nIntermediate-high risk PTC is defined as:\n\n1. Maximum tumor diameter \\>1 cm;\n2. Multifocal thyroid cancer;\n3. Local or distant metastasis;\n4. Primary lesion with extrathyroidal extension;\n5. Vascular invasion;\n6. Primary lesion with an invasive pathological subtype;\n7. History of head and neck radiotherapy during adolescence;\n8. Family history of thyroid cancer;\n9. Genetic testing revealing high-risk mutation combinations, such as BRAF V600E or RAS mutations with concurrent TERT or TP53 mutations, or RAS mutations combined with EIF1AX mutations.","70 Years",{"count":130,"type":18},201,"This study aims to investigate the efficacy and prognosis of ultrasound-guided and gene-based microwave ablation (MWA) versus surgical treatment in patients with low-risk papillary thyroid carcinoma (PTC). By analyzing genetic testing results, the study explores the impact of genetic mutations on treatment selection for low-risk patients, providing more precise molecular biological evidence for treatment choices and prognosis evaluation of thyroid cancer. This prospective study collects clinical data from patients diagnosed with PTC at Sun Yat-sen Memorial Hospital of Sun Yat-sen University between January 2022 and November 2024, who underwent genetic testing prior to treatment, and assesses efficacy and complications through long-term follow-up.",[26],[134,135,136,137],"Papillary Thyroid Carcinoma","Ablation Therapy","Personalized treatment","Thyroid cancer gene mutations","2024-12-25",{"date":140,"type":36},"2024-12-31",{"date":142,"type":36},"2022-01-01",{"date":144,"type":18},"2025-03-04",{"name":146,"class":43},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]